Curated News
By: NewsRamp Editorial Staff
October 02, 2024
GeoVax CEO to Discuss Innovative Cancer Therapies at ROTH Healthcare Conference
Discuss on Reddit
LinkedIn
Substack
Telegram
GithubTLDR
- GeoVax Labs, Inc. CEO to participate in panel on innovative therapies for solid tumors, gaining insights and networking opportunities.
- GeoVax is developing novel vaccines and cancer therapies, including a next-generation COVID-19 vaccine and gene-directed therapy for advanced cancers.
- GeoVax's clinical programs aim to provide effective vaccines for infectious diseases and innovative therapies for solid tumor cancers, contributing to improved global health.
- GeoVax's lead clinical program includes a next-generation COVID-19 vaccine, a multicenter Phase 1/2 clinical trial for advanced head and neck cancers, and ongoing updates on their website.
Impact - Why it Matters
This news matters as it highlights GeoVax Labs, Inc.'s efforts in developing novel vaccines for infectious diseases and therapies for solid tumor cancers, including a next-generation COVID-19 vaccine and a gene-directed therapy for advanced head and neck cancers. The participation of their CEO in the panel discussion signifies the company's commitment to advancing innovative treatments for life-threatening diseases.
Summary
GeoVax Labs, Inc. announced that its Chairman & CEO, David Dodd, will participate in a panel discussion on innovative therapies for solid tumors at the 3rd Annual ROTH Healthcare Opportunities Conference. The company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine, and they are also evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, GeoVax CEO to Discuss Innovative Cancer Therapies at ROTH Healthcare Conference
